Sangamo Therapeutics Inc $ 10.6 -0.31 (-2.84%)
Warning! GuruFocus has detected 3 Severe warning signs with SGMO. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for Sangamo Therapeutics Inc () from 2000 to Oct 20 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Sangamo Therapeutics stock (SGMO) PE ratio as of Oct 20 2020 is 0. More Details
Sangamo Therapeutics PE Ratio (TTM) Historical Data
View and export this data going back to 2000. Start your Free Trial
Sangamo Therapeutics PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:CRTX NAS:RGNX NAS:ADVM NYSE:ZYME NYSE:RCUS NAS:EDIT NAS:HRTX NAS:AKBA NAS:ZGNX NAS:CNST OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address 7000 Marina Boulevard, Brisbane, CA, USA, 94005
Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.